Go Pro

Henry Schein (HSIC) Competitors

Henry Schein logo
$85.65 -1.78 (-2.03%)
As of 03:22 PM Eastern
This is a fair market value price provided by Massive. Learn more.

HSIC vs. COO, IDXX, MMSI, PODD, and AMN

Should you buy Henry Schein stock or one of its competitors? Henry Schein's main competitors and comparable companies include Cooper Companies (COO), IDEXX Laboratories (IDXX), Merit Medical Systems (MMSI), Insulet (PODD), and AMN Healthcare Services (AMN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Henry Schein compare to Cooper Companies?

Cooper Companies (NASDAQ:COO) and Henry Schein (NASDAQ:HSIC) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

Cooper Companies has a beta of 0.82, meaning that its share price is 18% less volatile than the broader market. Comparatively, Henry Schein has a beta of 0.81, meaning that its share price is 19% less volatile than the broader market.

Cooper Companies has a net margin of 13.46% compared to Henry Schein's net margin of 2.96%. Henry Schein's return on equity of 15.97% beat Cooper Companies' return on equity.

Company Net Margins Return on Equity Return on Assets
Cooper Companies13.46% 10.90% 7.24%
Henry Schein 2.96%15.97%5.56%

24.4% of Cooper Companies shares are held by institutional investors. Comparatively, 96.6% of Henry Schein shares are held by institutional investors. 2.1% of Cooper Companies shares are held by insiders. Comparatively, 0.9% of Henry Schein shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Henry Schein has higher revenue and earnings than Cooper Companies. Cooper Companies is trading at a lower price-to-earnings ratio than Henry Schein, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cooper Companies$4.09B2.59$374.90M$2.9318.99
Henry Schein$13.18B0.73$398M$3.4325.04

Cooper Companies presently has a consensus target price of $71.47, indicating a potential upside of 28.42%. Henry Schein has a consensus target price of $92.93, indicating a potential upside of 8.22%. Given Cooper Companies' higher probable upside, equities analysts clearly believe Cooper Companies is more favorable than Henry Schein.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cooper Companies
2 Sell rating(s)
12 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.16
Henry Schein
1 Sell rating(s)
5 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.53

In the previous week, Cooper Companies had 38 more articles in the media than Henry Schein. MarketBeat recorded 43 mentions for Cooper Companies and 5 mentions for Henry Schein. Henry Schein's average media sentiment score of 0.81 beat Cooper Companies' score of 0.70 indicating that Henry Schein is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cooper Companies
12 Very Positive mention(s)
8 Positive mention(s)
11 Neutral mention(s)
9 Negative mention(s)
1 Very Negative mention(s)
Positive
Henry Schein
4 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Henry Schein beats Cooper Companies on 9 of the 16 factors compared between the two stocks.

How does Henry Schein compare to IDEXX Laboratories?

Henry Schein (NASDAQ:HSIC) and IDEXX Laboratories (NASDAQ:IDXX) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings.

Henry Schein has a beta of 0.81, meaning that its stock price is 19% less volatile than the broader market. Comparatively, IDEXX Laboratories has a beta of 1.54, meaning that its stock price is 54% more volatile than the broader market.

IDEXX Laboratories has lower revenue, but higher earnings than Henry Schein. Henry Schein is trading at a lower price-to-earnings ratio than IDEXX Laboratories, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Henry Schein$13.18B0.73$398M$3.4325.04
IDEXX Laboratories$4.30B9.49$1.06B$14.2236.46

IDEXX Laboratories has a net margin of 25.03% compared to Henry Schein's net margin of 2.96%. IDEXX Laboratories' return on equity of 71.96% beat Henry Schein's return on equity.

Company Net Margins Return on Equity Return on Assets
Henry Schein2.96% 15.97% 5.56%
IDEXX Laboratories 25.03%71.96%33.60%

Henry Schein presently has a consensus price target of $92.93, indicating a potential upside of 8.22%. IDEXX Laboratories has a consensus price target of $747.00, indicating a potential upside of 44.07%. Given IDEXX Laboratories' stronger consensus rating and higher probable upside, analysts plainly believe IDEXX Laboratories is more favorable than Henry Schein.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Henry Schein
1 Sell rating(s)
5 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.53
IDEXX Laboratories
0 Sell rating(s)
4 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.60

In the previous week, IDEXX Laboratories had 6 more articles in the media than Henry Schein. MarketBeat recorded 11 mentions for IDEXX Laboratories and 5 mentions for Henry Schein. Henry Schein's average media sentiment score of 0.81 beat IDEXX Laboratories' score of 0.64 indicating that Henry Schein is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Henry Schein
4 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
IDEXX Laboratories
5 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

96.6% of Henry Schein shares are owned by institutional investors. Comparatively, 87.8% of IDEXX Laboratories shares are owned by institutional investors. 0.9% of Henry Schein shares are owned by insiders. Comparatively, 0.8% of IDEXX Laboratories shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

IDEXX Laboratories beats Henry Schein on 11 of the 16 factors compared between the two stocks.

How does Henry Schein compare to Merit Medical Systems?

Henry Schein (NASDAQ:HSIC) and Merit Medical Systems (NASDAQ:MMSI) are both mid-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, risk, analyst recommendations, institutional ownership, profitability, valuation and earnings.

Merit Medical Systems has a net margin of 9.22% compared to Henry Schein's net margin of 2.96%. Henry Schein's return on equity of 15.97% beat Merit Medical Systems' return on equity.

Company Net Margins Return on Equity Return on Assets
Henry Schein2.96% 15.97% 5.56%
Merit Medical Systems 9.22%13.75%8.10%

Henry Schein presently has a consensus price target of $92.93, indicating a potential upside of 8.22%. Merit Medical Systems has a consensus price target of $100.00, indicating a potential upside of 13.92%. Given Merit Medical Systems' stronger consensus rating and higher probable upside, analysts plainly believe Merit Medical Systems is more favorable than Henry Schein.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Henry Schein
1 Sell rating(s)
5 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.53
Merit Medical Systems
0 Sell rating(s)
3 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.83

Henry Schein has a beta of 0.81, indicating that its share price is 19% less volatile than the broader market. Comparatively, Merit Medical Systems has a beta of 0.49, indicating that its share price is 51% less volatile than the broader market.

In the previous week, Henry Schein had 4 more articles in the media than Merit Medical Systems. MarketBeat recorded 5 mentions for Henry Schein and 1 mentions for Merit Medical Systems. Merit Medical Systems' average media sentiment score of 1.73 beat Henry Schein's score of 0.81 indicating that Merit Medical Systems is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Henry Schein
4 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Merit Medical Systems
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

96.6% of Henry Schein shares are held by institutional investors. Comparatively, 99.7% of Merit Medical Systems shares are held by institutional investors. 0.9% of Henry Schein shares are held by insiders. Comparatively, 0.7% of Merit Medical Systems shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Henry Schein has higher revenue and earnings than Merit Medical Systems. Henry Schein is trading at a lower price-to-earnings ratio than Merit Medical Systems, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Henry Schein$13.18B0.73$398M$3.4325.04
Merit Medical Systems$1.58B3.32$128.49M$2.4236.27

Summary

Merit Medical Systems beats Henry Schein on 9 of the 17 factors compared between the two stocks.

How does Henry Schein compare to Insulet?

Insulet (NASDAQ:PODD) and Henry Schein (NASDAQ:HSIC) are both mid-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, profitability, risk and valuation.

Insulet has a beta of 1.08, indicating that its stock price is 8% more volatile than the broader market. Comparatively, Henry Schein has a beta of 0.81, indicating that its stock price is 19% less volatile than the broader market.

Henry Schein has higher revenue and earnings than Insulet. Henry Schein is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Insulet$2.71B3.48$247.10M$5.3525.40
Henry Schein$13.18B0.73$398M$3.4325.04

Insulet currently has a consensus price target of $195.40, indicating a potential upside of 43.81%. Henry Schein has a consensus price target of $92.93, indicating a potential upside of 8.22%. Given Insulet's higher probable upside, analysts plainly believe Insulet is more favorable than Henry Schein.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Insulet
2 Sell rating(s)
11 Hold rating(s)
13 Buy rating(s)
0 Strong Buy rating(s)
2.42
Henry Schein
1 Sell rating(s)
5 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.53

Insulet has a net margin of 12.29% compared to Henry Schein's net margin of 2.96%. Insulet's return on equity of 29.29% beat Henry Schein's return on equity.

Company Net Margins Return on Equity Return on Assets
Insulet12.29% 29.29% 13.31%
Henry Schein 2.96%15.97%5.56%

In the previous week, Insulet and Insulet both had 5 articles in the media. Insulet's average media sentiment score of 0.89 beat Henry Schein's score of 0.81 indicating that Insulet is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Insulet
3 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Henry Schein
4 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

96.6% of Henry Schein shares are owned by institutional investors. 0.4% of Insulet shares are owned by insiders. Comparatively, 0.9% of Henry Schein shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Insulet beats Henry Schein on 10 of the 15 factors compared between the two stocks.

How does Henry Schein compare to AMN Healthcare Services?

Henry Schein (NASDAQ:HSIC) and AMN Healthcare Services (NYSE:AMN) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, valuation, media sentiment, risk, earnings and profitability.

Henry Schein presently has a consensus price target of $92.93, indicating a potential upside of 8.22%. AMN Healthcare Services has a consensus price target of $36.00, indicating a potential upside of 6.21%. Given Henry Schein's stronger consensus rating and higher possible upside, analysts plainly believe Henry Schein is more favorable than AMN Healthcare Services.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Henry Schein
1 Sell rating(s)
5 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.53
AMN Healthcare Services
0 Sell rating(s)
4 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50

AMN Healthcare Services has a net margin of 3.06% compared to Henry Schein's net margin of 2.96%. AMN Healthcare Services' return on equity of 19.92% beat Henry Schein's return on equity.

Company Net Margins Return on Equity Return on Assets
Henry Schein2.96% 15.97% 5.56%
AMN Healthcare Services 3.06%19.92%5.93%

In the previous week, Henry Schein had 1 more articles in the media than AMN Healthcare Services. MarketBeat recorded 5 mentions for Henry Schein and 4 mentions for AMN Healthcare Services. Henry Schein's average media sentiment score of 0.81 beat AMN Healthcare Services' score of 0.55 indicating that Henry Schein is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Henry Schein
4 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
AMN Healthcare Services
3 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Henry Schein has a beta of 0.81, indicating that its stock price is 19% less volatile than the broader market. Comparatively, AMN Healthcare Services has a beta of 0.38, indicating that its stock price is 62% less volatile than the broader market.

Henry Schein has higher revenue and earnings than AMN Healthcare Services. AMN Healthcare Services is trading at a lower price-to-earnings ratio than Henry Schein, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Henry Schein$13.18B0.73$398M$3.4325.04
AMN Healthcare Services$2.73B0.48-$95.70M$2.6812.65

96.6% of Henry Schein shares are held by institutional investors. Comparatively, 99.2% of AMN Healthcare Services shares are held by institutional investors. 0.9% of Henry Schein shares are held by company insiders. Comparatively, 1.1% of AMN Healthcare Services shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Henry Schein beats AMN Healthcare Services on 11 of the 16 factors compared between the two stocks.

Get Henry Schein News Delivered to You Automatically

Sign up to receive the latest news and ratings for HSIC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HSIC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HSIC vs. The Competition

MetricHenry ScheinHealthcare Providers & Services IndustryHealthcare SectorNASDAQ Exchange
Market Cap$9.58B$9.70B$7.20B$13.11B
Dividend YieldN/A2.61%2.53%13.00%
P/E Ratio25.0634.51274.6925.74
Price / Sales0.734.95644.1085.75
Price / Cash10.95121.8176.3152.02
Price / Book2.595.2210.446.31
Net Income$398M$315.70M$3.49B$359.73M
7 Day Performance-1.03%-1.32%0.66%1.59%
1 Month Performance-2.97%-2.70%-3.30%-3.46%
1 Year Performance24.08%11.55%16.20%5.79%

Henry Schein Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HSIC
Henry Schein
2.5399 of 5 stars
$85.65
-2.0%
$92.93
+8.5%
+28.7%$9.55B$13.18B24.9825,000
COO
Cooper Companies
4.5275 of 5 stars
$54.22
+0.6%
$71.47
+31.8%
-18.7%$10.25B$4.24B18.5115,000
IDXX
IDEXX Laboratories
4.1513 of 5 stars
$509.56
+1.0%
$747.00
+46.6%
-19.0%$40.14B$4.55B35.8311,000
MMSI
Merit Medical Systems
3.2639 of 5 stars
$87.02
+0.8%
$100.00
+14.9%
+4.4%$5.16B$1.52B35.967,500
PODD
Insulet
4.087 of 5 stars
$137.80
+4.4%
$195.40
+41.8%
-58.4%$9.15B$3.05B25.765,400

Related Companies and Tools


This page (NASDAQ:HSIC) was last updated on 9/23/2026 by MarketBeat.com Staff.
From Our Partners